LA BioMed investigators help spearhead study about novel approach to acute COPD illness

September 6, 2011

Richard Casaburi, Ph.D., M.D., principal investigator at Los Angeles Biomedical Research Institute, is co-author of a recent study that should help improve the condition for the millions of individuals who suffer from chronic obstructive pulmonary disease, better known as COPD. The results of the study reveal that adding a common antibiotic - azithromycin – to the usual daily treatment for COPD reduced the occurrence of acute exacerbations by 27% and tended to improve the quality of life for COPD patients. The results of the study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, appeared in the Aug. 25 issue of the New England Journal of Medicine.

"This important study adds to a growing number of approaches that reduce the frequency of COPD illnesses," said Dr. Casaburi. "Together, they promise COPD patients who avail themselves of readily-available therapies substantially reduced risk of acute lung illnesses. This has the potential to reduce the misery this disease brings and can also can bring down medical costs, as more than half of COPD costs are related to hospitalization for COPD-related illnesses."

COPD is a progressive disease of the lungs that affects about 24 million people in the United States and is now the third leading cause of death in this country. Many patients experience acute COPD-related illnesses ("exacerbations"), which are sudden onsets of worsened cough, wheeze, and labored breathing that are typically induced by bacterial and/or viral infection. Previous research had suggested that the antibiotic might decrease COPD exacerbations, but this study was the first to enroll a large number of COPD patients and treat exacerbations with this drug over a full year. Participants had a history of exacerbations in the previous year or needed oxygen therapy.

At 10 regional centers around the United States, the study recruited 558 study participants who took 250 mg of azithromycin daily for a year, in addition to their usual care. They averaged 1.48 acute COPD exacerbations annually, compared to 1.83 exacerbations for the 559 participants who received traditional care without azithromycin. The participants taking azithromycin also tended to report more favorable breathing ability and overall well-being.

Dr. Casaburi leads the Rehabilitation Clinical Trials Center, where over 50 research studies have been performed aimed at improving the lives of with COPD. While there is currently no cure, a combination of drugs and lifestyle changes can help manage COPD symptoms.

Explore further: Commonly prescribed antibiotic reduces acute COPD attacks

Provided by: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

shares

Related Stories

Commonly prescribed antibiotic reduces acute COPD attacks

August 24, 2011
Adding a common antibiotic to the usual daily treatment regimen for chronic obstructive pulmonary disease (COPD) can reduce the occurrence of acute exacerbations and improve quality of life, reports new results from a clinical ...

Computed tomography shows changes in lungs associated with COPD flare-ups

July 27, 2011
Using computed tomography (CT), researchers have identified two types of structural changes in the lungs of patients with chronic obstructive pulmonary disease (COPD) that are associated with frequent exacerbations, or episodes ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.